SCLX

Scilex Holding Co. 10-Q Summary: Period Ended June 30, 2026

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for Scilex Holding Company (SCLX) for the period ended June 30, 2026. Scilex is a biopharmaceutical company focused on non-opioid pain management products, including ZTlido, ELYXYB, and GLOPERBA, alongside a pipeline of candidates (SP-102, SP-103, SP-104). The company also pursues a cryptocurrency treasury strategy and holds significant equity interests in Datavault AI, Inc. and Vivasor Holding Company. The filing includes a "Going Concern" warning due to substantial accumulated deficits and negative working capital.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net revenue increased by $1.4 million (9.1%) year-over-year, driven primarily by $3.8 million in contract revenue from the newly consolidated Vivasor subsidiary and growth in ELYXYB sales. This was partially offset by a $2.9 million decrease in ZTlido sales due to inventory shipment delays from Japan.
• Operating Expenses: Total operating costs increased by $14.5 million to $77.8 million. Selling, General, and Administrative (SG&A) expenses rose by $11.1 million, largely due to increased legal fees, advisory costs, and facility expenses. Research and Development (R&D) expenses decreased by $2.1 million, primarily due to the absence of one-time acquisition costs for the KDS2010 license incurred in the prior year.
• Non-Operating Items: The net loss was significantly impacted by non-cash fair value adjustments. Notable items include an $82.4 million unrealized loss on the Datavault equity method investment, a $27.3 million unrealized loss on digital assets (Bitcoin), and a $28.8 million loss on the compound derivative related to the terminated Scilex-St. James Loan Agreement.
• Balance Sheet: Cash reserves depleted from $5.0 million to $0.6 million. Total assets decreased from $365.0 million to $253.6 million, reflecting the write-down of digital assets and equity investments. Total liabilities decreased slightly to $564.1 million.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year following the issuance date. The company has negative working capital of $476 million and an accumulated deficit exceeding $1 billion. Future operations depend on successful fundraising, commercialization of products, or strategic transactions.
• Debt Obligations: Significant debt maturities are approaching. The Oramed Note (principal and PIK interest of $29.5 million) and Tranche B Notes ($12.6 million) have been extended to September 30, 2026. Failure to repay could trigger default provisions, including mandatory conversion or acceleration.
• Legal Proceedings:
  • St. James Loan Lawsuit: The company filed a complaint against St. James Bank & Trust alleging unauthorized sale of pledged Datavault shares. The loan agreement was terminated in March 2026, resulting in the loss of control over 95.7 million Datavault shares and a $28.8 million derivative loss.
  • Patent Litigation: The Federal Circuit affirmed a lower court decision that a generic version of ZTlido does not infringe Scilex's patents, posing a risk to future ZTlido revenue.
  • StockBlock Complaint: A complaint filed in July 2026 alleges breach of an exclusive engagement agreement, seeking damages of approximately $10 million.
• Strategic Transactions: The company has entered into term sheets for a $100 million investment from iHolding Group and a $120 million contribution to Datavault, but these are not yet definitive and closing is not guaranteed.

Key Facts for Investor Verification

• Liquidity Crisis: Verify the company's ability to raise capital immediately given cash on hand of only $0.6 million and debt due in September 2026.
• Datavault Exposure: Confirm the current status of the Datavault investment ($56.6 million carrying value) and the impact of the St. James lawsuit on the company's ability to monetize these assets.
• ZTlido Patent Status: Assess the commercial impact of the Federal Circuit ruling affirming non-infringement of ZTlido patents by a generic competitor.
• Debt Extensions: Monitor the September 30, 2026, maturity of the Oramed Note and Tranche B Notes and the likelihood of further extensions or refinancing.
• Revenue Concentration: Note that four customers accounted for 95% of revenue in the six months ended June 30, 2026, creating significant concentration risk.